Somatic, hematologic phenotype, long-term outcome, and effect of hematopoietic stem cell transplantation. An analysis of 97 Fanconi anemia patients from the Italian national database on behalf of the Marrow Failure Study Group of the AIEOP (Italian Association of Pediatric Hematology–Oncology)

Johanna Svahn, Francesca Bagnasco, Enrico Cappelli, Daniela Onofrillo, Silvia Caruso, Fabio Corsolini, Daniela De Rocco, Anna Savoia, Daniela Longoni, Marta Pillon, Nicoletta Marra, Ugo Ramenghi, Piero Farruggia, Anna Locasciulli, Carmen Addari, Carla Cerri, Elena Mastrodicasa, Gabriella Casazza, Federico Verzegnassi, Francesca RiccardiRiccardo Haupt, Angelica Barone, Simone Cesaro, Chiara Cugno, Carlo Dufour

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We analyzed 97 Fanconi anemia patients from a clinic/biological database for genotype, somatic, and hematologic phenotype, adverse hematological events, solid tumors, and treatment. Seventy-two patients belonged to complementation group A. Eighty percent of patients presented with mild/moderate somatic phenotype and most with cytopenia. No correlation was seen between somatic/hematologic phenotype and number of missense mutations of FANCA alleles. Over follow-up, 33% of patients improved or maintained mild/moderate cytopenia or normal blood count, whereas remaining worsened cytopenia. Eleven patients developed a hematological adverse event (MDS, AML, pathological cytogenetics) and three developed solid tumors. 10 years cumulative risk of death of the whole cohort was 25.6% with median follow-up 5.8 years. In patients eligible to hematopoietic stem cell transplantation because of moderate cytopenia, mortality was significantly higher in subjects transplanted from matched unrelated donor over nontransplanted subjects, whereas there was no significant difference between matched sibling donor transplants and nontransplanted patients. In patients eligible to transplant because of severe cytopenia and clonal disease, mortality risk was not significantly different in transplanted from matched unrelated versus matched sibling donor versus nontransplanted subjects. The decision to transplant should rely on various elements including, type of donor, HLA matching, patient comorbidities, impairment, and clonal evolution of hematopoiesis. Am. J. Hematol. 91:666–671, 2016.

Original languageEnglish
Pages (from-to)666-671
Number of pages6
JournalAmerican Journal of Hematology
Volume91
Issue number7
DOIs
Publication statusPublished - 1 Jul 2016
Externally publishedYes

Fingerprint

Fanconi Anemia
Hematopoietic Stem Cell Transplantation
Bone Marrow
Databases
Pediatrics
Phenotype
Tissue Donors
Siblings
Clonal Evolution
Transplants
Unrelated Donors
Mortality
Hematopoiesis
Missense Mutation
Cytogenetics
Comorbidity
Neoplasms
Alleles
Genotype

ASJC Scopus subject areas

  • Hematology

Cite this

Somatic, hematologic phenotype, long-term outcome, and effect of hematopoietic stem cell transplantation. An analysis of 97 Fanconi anemia patients from the Italian national database on behalf of the Marrow Failure Study Group of the AIEOP (Italian Association of Pediatric Hematology–Oncology). / Svahn, Johanna; Bagnasco, Francesca; Cappelli, Enrico; Onofrillo, Daniela; Caruso, Silvia; Corsolini, Fabio; De Rocco, Daniela; Savoia, Anna; Longoni, Daniela; Pillon, Marta; Marra, Nicoletta; Ramenghi, Ugo; Farruggia, Piero; Locasciulli, Anna; Addari, Carmen; Cerri, Carla; Mastrodicasa, Elena; Casazza, Gabriella; Verzegnassi, Federico; Riccardi, Francesca; Haupt, Riccardo; Barone, Angelica; Cesaro, Simone; Cugno, Chiara; Dufour, Carlo.

In: American Journal of Hematology, Vol. 91, No. 7, 01.07.2016, p. 666-671.

Research output: Contribution to journalArticle

Svahn, J, Bagnasco, F, Cappelli, E, Onofrillo, D, Caruso, S, Corsolini, F, De Rocco, D, Savoia, A, Longoni, D, Pillon, M, Marra, N, Ramenghi, U, Farruggia, P, Locasciulli, A, Addari, C, Cerri, C, Mastrodicasa, E, Casazza, G, Verzegnassi, F, Riccardi, F, Haupt, R, Barone, A, Cesaro, S, Cugno, C & Dufour, C 2016, 'Somatic, hematologic phenotype, long-term outcome, and effect of hematopoietic stem cell transplantation. An analysis of 97 Fanconi anemia patients from the Italian national database on behalf of the Marrow Failure Study Group of the AIEOP (Italian Association of Pediatric Hematology–Oncology)', American Journal of Hematology, vol. 91, no. 7, pp. 666-671. https://doi.org/10.1002/ajh.24373
Svahn, Johanna ; Bagnasco, Francesca ; Cappelli, Enrico ; Onofrillo, Daniela ; Caruso, Silvia ; Corsolini, Fabio ; De Rocco, Daniela ; Savoia, Anna ; Longoni, Daniela ; Pillon, Marta ; Marra, Nicoletta ; Ramenghi, Ugo ; Farruggia, Piero ; Locasciulli, Anna ; Addari, Carmen ; Cerri, Carla ; Mastrodicasa, Elena ; Casazza, Gabriella ; Verzegnassi, Federico ; Riccardi, Francesca ; Haupt, Riccardo ; Barone, Angelica ; Cesaro, Simone ; Cugno, Chiara ; Dufour, Carlo. / Somatic, hematologic phenotype, long-term outcome, and effect of hematopoietic stem cell transplantation. An analysis of 97 Fanconi anemia patients from the Italian national database on behalf of the Marrow Failure Study Group of the AIEOP (Italian Association of Pediatric Hematology–Oncology). In: American Journal of Hematology. 2016 ; Vol. 91, No. 7. pp. 666-671.
@article{a4233d7aca2f4eb1b0eacd939004d378,
title = "Somatic, hematologic phenotype, long-term outcome, and effect of hematopoietic stem cell transplantation. An analysis of 97 Fanconi anemia patients from the Italian national database on behalf of the Marrow Failure Study Group of the AIEOP (Italian Association of Pediatric Hematology–Oncology)",
abstract = "We analyzed 97 Fanconi anemia patients from a clinic/biological database for genotype, somatic, and hematologic phenotype, adverse hematological events, solid tumors, and treatment. Seventy-two patients belonged to complementation group A. Eighty percent of patients presented with mild/moderate somatic phenotype and most with cytopenia. No correlation was seen between somatic/hematologic phenotype and number of missense mutations of FANCA alleles. Over follow-up, 33{\%} of patients improved or maintained mild/moderate cytopenia or normal blood count, whereas remaining worsened cytopenia. Eleven patients developed a hematological adverse event (MDS, AML, pathological cytogenetics) and three developed solid tumors. 10 years cumulative risk of death of the whole cohort was 25.6{\%} with median follow-up 5.8 years. In patients eligible to hematopoietic stem cell transplantation because of moderate cytopenia, mortality was significantly higher in subjects transplanted from matched unrelated donor over nontransplanted subjects, whereas there was no significant difference between matched sibling donor transplants and nontransplanted patients. In patients eligible to transplant because of severe cytopenia and clonal disease, mortality risk was not significantly different in transplanted from matched unrelated versus matched sibling donor versus nontransplanted subjects. The decision to transplant should rely on various elements including, type of donor, HLA matching, patient comorbidities, impairment, and clonal evolution of hematopoiesis. Am. J. Hematol. 91:666–671, 2016.",
author = "Johanna Svahn and Francesca Bagnasco and Enrico Cappelli and Daniela Onofrillo and Silvia Caruso and Fabio Corsolini and {De Rocco}, Daniela and Anna Savoia and Daniela Longoni and Marta Pillon and Nicoletta Marra and Ugo Ramenghi and Piero Farruggia and Anna Locasciulli and Carmen Addari and Carla Cerri and Elena Mastrodicasa and Gabriella Casazza and Federico Verzegnassi and Francesca Riccardi and Riccardo Haupt and Angelica Barone and Simone Cesaro and Chiara Cugno and Carlo Dufour",
year = "2016",
month = "7",
day = "1",
doi = "10.1002/ajh.24373",
language = "English",
volume = "91",
pages = "666--671",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Somatic, hematologic phenotype, long-term outcome, and effect of hematopoietic stem cell transplantation. An analysis of 97 Fanconi anemia patients from the Italian national database on behalf of the Marrow Failure Study Group of the AIEOP (Italian Association of Pediatric Hematology–Oncology)

AU - Svahn, Johanna

AU - Bagnasco, Francesca

AU - Cappelli, Enrico

AU - Onofrillo, Daniela

AU - Caruso, Silvia

AU - Corsolini, Fabio

AU - De Rocco, Daniela

AU - Savoia, Anna

AU - Longoni, Daniela

AU - Pillon, Marta

AU - Marra, Nicoletta

AU - Ramenghi, Ugo

AU - Farruggia, Piero

AU - Locasciulli, Anna

AU - Addari, Carmen

AU - Cerri, Carla

AU - Mastrodicasa, Elena

AU - Casazza, Gabriella

AU - Verzegnassi, Federico

AU - Riccardi, Francesca

AU - Haupt, Riccardo

AU - Barone, Angelica

AU - Cesaro, Simone

AU - Cugno, Chiara

AU - Dufour, Carlo

PY - 2016/7/1

Y1 - 2016/7/1

N2 - We analyzed 97 Fanconi anemia patients from a clinic/biological database for genotype, somatic, and hematologic phenotype, adverse hematological events, solid tumors, and treatment. Seventy-two patients belonged to complementation group A. Eighty percent of patients presented with mild/moderate somatic phenotype and most with cytopenia. No correlation was seen between somatic/hematologic phenotype and number of missense mutations of FANCA alleles. Over follow-up, 33% of patients improved or maintained mild/moderate cytopenia or normal blood count, whereas remaining worsened cytopenia. Eleven patients developed a hematological adverse event (MDS, AML, pathological cytogenetics) and three developed solid tumors. 10 years cumulative risk of death of the whole cohort was 25.6% with median follow-up 5.8 years. In patients eligible to hematopoietic stem cell transplantation because of moderate cytopenia, mortality was significantly higher in subjects transplanted from matched unrelated donor over nontransplanted subjects, whereas there was no significant difference between matched sibling donor transplants and nontransplanted patients. In patients eligible to transplant because of severe cytopenia and clonal disease, mortality risk was not significantly different in transplanted from matched unrelated versus matched sibling donor versus nontransplanted subjects. The decision to transplant should rely on various elements including, type of donor, HLA matching, patient comorbidities, impairment, and clonal evolution of hematopoiesis. Am. J. Hematol. 91:666–671, 2016.

AB - We analyzed 97 Fanconi anemia patients from a clinic/biological database for genotype, somatic, and hematologic phenotype, adverse hematological events, solid tumors, and treatment. Seventy-two patients belonged to complementation group A. Eighty percent of patients presented with mild/moderate somatic phenotype and most with cytopenia. No correlation was seen between somatic/hematologic phenotype and number of missense mutations of FANCA alleles. Over follow-up, 33% of patients improved or maintained mild/moderate cytopenia or normal blood count, whereas remaining worsened cytopenia. Eleven patients developed a hematological adverse event (MDS, AML, pathological cytogenetics) and three developed solid tumors. 10 years cumulative risk of death of the whole cohort was 25.6% with median follow-up 5.8 years. In patients eligible to hematopoietic stem cell transplantation because of moderate cytopenia, mortality was significantly higher in subjects transplanted from matched unrelated donor over nontransplanted subjects, whereas there was no significant difference between matched sibling donor transplants and nontransplanted patients. In patients eligible to transplant because of severe cytopenia and clonal disease, mortality risk was not significantly different in transplanted from matched unrelated versus matched sibling donor versus nontransplanted subjects. The decision to transplant should rely on various elements including, type of donor, HLA matching, patient comorbidities, impairment, and clonal evolution of hematopoiesis. Am. J. Hematol. 91:666–671, 2016.

UR - http://www.scopus.com/inward/record.url?scp=84973867711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973867711&partnerID=8YFLogxK

U2 - 10.1002/ajh.24373

DO - 10.1002/ajh.24373

M3 - Article

C2 - 27013026

AN - SCOPUS:84973867711

VL - 91

SP - 666

EP - 671

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -